Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP

• Published in: British journal of cancer Vol. 124; no. 4; pp. 721 - 727
• Main Authors: Folprecht, Gunnar, Trautmann, Karolin, Stein, Alexander, Huebner, Gerdt, Stahl, Michael, Kasper, Stefan, Kretzschmar, Albrecht, Köhne, Claus-Henning, Grünwald, Viktor, Hofheinz, Ralf-Dieter, Schütte, Katharina, Löffler, Harald, Bokemeyer, Carsten, Krämer, Alwin
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 16.02.2021; Nature Publishing Group
• Subjects: 631/67; 631/67/1059; Adverse events; Biomedical and Life Sciences; Biomedicine; Cancer Research; Carboplatin; Chemotherapy; Drug Resistance; Epidemiology; Epidermal growth factor receptors; Immunotherapy; Medical prognosis; Metastases; Molecular Medicine; Monoclonal antibodies; Oncology; Paclitaxel; Patients; Targeted cancer therapy; Toxicity
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/s41416-020-01141-8

Background Patients with carcinoma of unknown primary (CUP) have a dismal prognosis, even when treated with multi-agent chemotherapy. We hypothesised that adding the epidermal growth-factor receptor (EGFR) inhibitor cetuximab to standard first-line chemotherapy with paclitaxel and carboplatin would improve PFS and RR in unfavourable CUP. Methods This open-labelled, multicentre Phase 2 study included patients with unfavourable, untreated adeno- or undifferentiated CUP. Patients were randomised to receive either paclitaxel/carboplatin (group A) or paclitaxel/carboplatin plus cetuximab (group B) every 3 weeks for a maximum of 6 cycles followed by cetuximab maintenance in group B. The primary endpoint was PFS in the two groups. Secondary endpoints were RR, toxicity and overall survival (OS). Results One-hundred-and-fifty patients were randomised (group A = 72, group B = 78). The median PFS and OS for all patients were 3.8 and 8.1 months (95% confidence interval (CI): 2.9–4.8 and 6.8–9.5). There was no significant difference in PFS (3.7 vs 4.6 months, HR 0.98) or OS (8.1 vs 7.4, HR 1.1) between the two treatment groups. Response rate tended to be better for chemotherapy plus cetuximab compared to chemotherapy alone (22% vs 15%). Adverse events grade ≥3 were comparable between the two groups, except for significantly increased skin toxicity in the cetuximab arm. Conclusions Cetuximab plus paclitaxel/carboplatin did not improve PFS, OS and RR in metastatic CUP compared to paclitaxel/carboplatin alone. Addition of cetuximab resulted in additional skin toxicity. Clinical trial registration The study was registered at clinicaltrials.gov as NCT00894569.